Breyfogle
Established Member
- Reaction score
- 146
Finasteride (ALM12845) - androgenetic alopecia On the 26th of September the Marketing Authorization Application (MAA) was submitted for Finasteride.
The product is a cutaneous spray, solution has been demonstrated to be safe and effective in the topical treatment of adult men with male pattern hair loss (androgenetic alopecia, Androgenetic Alopecia).
The product is subject to medical prescription. First national phase approval is estimated in 2020 or early 2021 in Europe.
https://www.almirall.com/documents/...1840-9b57657b48df?version=1.0&t=1572246472291
The product is a cutaneous spray, solution has been demonstrated to be safe and effective in the topical treatment of adult men with male pattern hair loss (androgenetic alopecia, Androgenetic Alopecia).
The product is subject to medical prescription. First national phase approval is estimated in 2020 or early 2021 in Europe.
https://www.almirall.com/documents/...1840-9b57657b48df?version=1.0&t=1572246472291